Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Revolution Medicines Inc. Common Stock — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.28 (market cap $28.69M), while Revolution Medicines Inc. Common Stock trades at $186.59 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 1405.4× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 60 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| QDTY | RVMD | |
|---|---|---|
Market Cap | $28.69M | $40.32B |
Volume | 22,490 | 4,855,734 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $221.15 |
52-Week Low | $36.57 | $47.50 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $37.02B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
